



## Fast Facts

Ticker	<b>ORY.MC / ORY.SM</b>
Exchange	Madrid Stock Exchange
Stock Price <sup>1</sup>	€2.19
Market Cap <sup>1</sup>	€117.5M
Cash <sup>2</sup>	€27.8M
Cash Runway	Q2:2024
Outstanding Shares	53.7M
52-Week Trading Range (€)	1.98-3.35
Avg. Daily Volume (30-day)	122,976
Headquarters	Barcelona, Spain
Fiscal Year End	December 31 <sup>st</sup>

## Analyst Research Coverage

Jefferies	Lucy Codrington
Roth Capital	Jonathan Aschoff
Ladenburg Thalmann	Ahu Demir
Kempen	Jacob Mekhael
Rx Securities	Joseph Hedden
Edison	Soo Romanov
Invest Securities	Jamila El Bougrini
Estrategias de Inversión	María Mira
El Análisis de:	Luis Navía

## Pioneering personalized medicine in epigenetics

ORYZON is a clinical stage biopharmaceutical company and a leader in the development of epigenetics-based therapeutics. We are developing two Phase II small molecule inhibitors of Lysine Specific Demethylase 1 (LSD1): **vafidemstat** and **iadademstat**, in two distinct therapeutic fields – CNS disorders and oncology.

Our experienced trans-Atlantic management team with vast drug development experience leverages key collaborations with prestigious clinical centers (Johns Hopkins, Columbia, Mount Sinai, Fox Chase Cancer Center) to optimize development efficiency.

Our expanding Phase II for both molecules builds on a clear demonstration of safety. Over 400 subjects treated (300+ vafidemstat; 100+ iadademstat), including elderly and unfit patients.


### Vafidemstat:

- First and only LSD1 inhibitor in CNS disorders. Currently in two Phase IIb trials in Borderline Personality Disorder (BPD) and Schizophrenia (SCZ)
- Near-term new Phase I/II personalized medicine trial for Kabuki syndrome (neurodevelopmental syndrome)

### Iadademstat:

- Finalizing PoC Phase II trial in elderly-unfit acute myeloid leukemia (Unfit AML) - ALICE trial
- New Phase Ib/II and Ib trials in 2022 in small cell lung cancer (SCLC) with registrational potential and in R/R-AML (OD designation received)
- New collaborative Phase II basket trial in 2022 with Fox Chase Cancer Center in neuroendocrine tumors

### A Proof Of Concept in AML (ALICE)



### CNS: vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor

Indication	Borderline Personality Disorder	Schizophrenia Negative Symptoms & Cognition	Kabuki Syndrome	SetD1A Compass related SCZ	Aggression in AD
Study	PORTICO	EVOLUTION	HOPE	New Study	New Study Continuation of REIMAGINE-AD
Phase	Phase IIb	Phase IIb	Phase Ib/II	Phase Ib/II	
Status	Recruiting	Recruiting	IND in preparation	Under study	Under study
Anticipated Milestones	Interim analysis 1Q23	Study updates 2023	IND 2H22/FPI 2023		

### Oncology: iadademstat (ORY-1001) - Selective LSD1 inhibitor

Indication	AML 1L Elderly/Unfit	AML R/R-Fit3mut+	ED-SCLC 1L	NETs R/R
Study	ALICE (Combo w azacitidine)	FRIDA (Combo w gilteritinib)	STELLAR (Combo w ICI)	NET Basket (Combo w other agents)
Phase	Phase IIa	Phase Ib	Phase Ib/II	Phase II
Status	Ongoing – fully enrolled	IND approved	IND in preparation	IND approved (Collaborative Study w FCCC)
Anticipated Milestones	2H22 ASH Final Data	FPI 2H22	IND 2H22	FPI 2H22

Note: Finalized clinical trials for iadademstat and vafidemstat are not shown. See [www.oryzon.com](http://www.oryzon.com) for more details

<sup>1</sup> as of 2022.11.09 / <sup>2</sup> as of 2022.09.30

\*Opinions, estimates or forecasts regarding Oryzon's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Oryzon or its management. Oryzon does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

## Management

**Carlos Buesa Arjol, PhD**  
Chief Executive Officer



**Douglas Faller MD, PhD**  
Global Chief Medical Officer



**Michael Ropacki, MD, PhD**  
Chief Medical Officer CNS



**Saikat Nandi, PhD**  
Global Chief Business Officer



**Ana Limón, PhD**  
Sr. VP Clinical Dev & Medical Affairs



**Jordi Xaus, PhD**  
Chief Scientific Officer



**Sonia Gutierrez, MSc**  
Director of Clinical Operations



**Neus Virgili, EPA**  
Chief IP Officer



**Enric Rello, PhD**  
Chief Financial Officer



This communication contains forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects," "anticipates," and similar expressions. Investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the CNMV, which are accessible to the public. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof.

## Market Opportunity in CNS Vafidemstat

**Borderline personality disorder**  
Ongoing Phase IIb

9M patients in US & EU - No approved drugs to date. Low competition: only 2 Phase II trials ongoing. Patients are given off-label antipsychotics



Estimated market value ~\$2.5B, expected to grow to \$3B by 2027



2 main types of symptoms: Unstable-extreme interpersonal relationships and aggression & self-aggression




Vafidemstat improves symptoms in pre-clinical models



**Kabuki syndrome**  
New Phase Ib/II (to start in 2023)

10,000 patients with KS WW with Access to advanced health care



■ KS-I 12-25 yrs old ■ KS-I 5-12 yrs old  
■ KS-I 2-5 yrs old ■ KS-II

Estimated Market Value ~0.7 Billion

Kabuki syndrome is one of the genetically driven pathologies where LSD1i compensates functional deficits. Opportunity for multiple label extensions

## Market Opportunity in Oncology Iadademstat

**Significant market opportunity in oncology, particularly where mutations in FLT3 (FLT3mut) increases risk of relapse**

Flt3mut occur in 30-40% of AML patients (+6,000 patients per year in US).



US Market potential Flt3mut R/R AML ~\$0.8B by 2028



SCLC is 15% of lung cancer (~50,000 patients in US and EU5; ~100,000 in China)



Global market potential first-line SCLC ~\$3.5B by 2027




Additional opportunities in neuroendocrine and other solid tumors




*Nature Reviews Drug Discovery 19, 233-234 (2020)*  
*Nature Reviews Drug Discovery 19, 507-508 (2020)*

### AML market



### SCLC market



## General Information

[info@oryzon.com](mailto:info@oryzon.com)

[www.oryzon.com](http://www.oryzon.com)

## Company Contact

Sai Nandi, CBO

[snandi@oryzon.com](mailto:snandi@oryzon.com)

## Investor Relations Contact

Ashley R. Robinson

[arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)